Media Release

 | Quelle: Novartis Pharma AG Novartis Pharma AG

Basel, 20 May 2003 - New data from a large pivotal US trial demonstrates ZelmacÒ* (tegaserod) was significantly more effective than placebo in providing rapid and sustained relief from chronic constipation based on a trial of more than 1,300 patients. Furthermore, Zelmac provided relief of several chronic constipation symptoms including bowel movement frequency, straining, stool consistency, abdominal discomfort or pain, bloating or distension.

Anhänge

Media Release
GlobeNewswire

Empfohlene Lektüre